Table 8Pooled results describing the risk of recurrent VTE for probands with VTE compared to probands without mutations

MutationStudies, NStudies With Data Appropriate for the Pooled Odds Ratio, nIndividuals Contributing to the Pooled Odds Ratio*, nPooled Odds Ratio (95% CI)
Heterozygous FVL141347301.56 (1.14–2.12)
Homozygous FVL9823822.65 (1.18–5.97)
Unspecified FVL§833621.56 (0.75–3.25)
Double Heterozygous FVL and PT 20210A438434.81 (0.50–46)
Heterozygous PT 20210A111036361.45 (0.96–2.21)
Mixed PT 20210A7411430.73 (0.37–1.44)
Homozygous PT 20210A2NANANA

studies without comparison groups or having zero events in both arms are not included

unadjusted odds ratios, relative to probands without mutations

the count includes both arms of a study that reported results separately for drug- versus placebo-treated patients


unspecified means that heterozygous and homozygous individuals were not distinguished in the study CI = confidence interval; FVL = Factor V Leiden; NA = not applicable; PT 20210A = prothrombin G20210A; VTE = venous thromboembolism

From: 3, Results

Cover of Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism
Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism.
Evidence Reports/Technology Assessments, No. 180.
Segal JB, Brotman DJ, Emadi A, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.